In a syngeneic murine model of HNSCC, the concurrent use of cisplatin and PD-1/PD-L1 blockade delayed tumor growth and enhanced survival without significantly reducing the number or function of TILs or increasing the cisplatin-induced toxicity (46). The gene discussed is CD274; the disease is neoplasm.